AbbVie Inc. (BCBA:ABBV)

Market Cap	348.25T
Revenue (ttm)	58.08T
Net Income (ttm)	4.37T
Shares Out	n/a
EPS (ttm)	2,464.09
PE Ratio	79.70
Forward PE	n/a
Dividend	488.77 (2.44%)
Ex-Dividend Date	Apr 15, 2025

Volume	1,183
Average Volume	910
Open	23,650
Previous Close	22,000
Day's Range	20,000 - 21,550
52-Week Range	12,412 - 27,925
Beta	n/a
RSI	23.17
Earnings Date	Apr 25, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: ABBV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD